



- **Voting results of Theradiag's Annual Ordinary and Extraordinary General Meeting**
- **Confidence in the new management team confirmed with the ratification of the cooptation of Bertrand de Castelnaud, Chief Executive Officer (CEO), as a Board member**

Croissy-Beaubourg, June 3, 2018, 6pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces the voting results of its Annual Ordinary and Extraordinary General Meeting, held on May 16th, 2019 at the offices of Fieldfisher Paris, 48 rue Cambon, 75001 Paris.

Following (i) the change in the company's Governance (Bertrand de Castelnaud's appointment as CEO as of 21st January 2019), (ii) the end of the legal dispute with HOB Biotech, and (iii) the recent signature of new agreements and partnerships, it was all the more important for Theradiag to gather its shareholders, both institutional and private, at this major event that is its Annual General Meeting.

In this context, on May 16th, the number of shares held by shareholders being present or represented at the Meeting was 2,586,053, hence a quorum of 30.18%.

All resolutions of the Ordinary General Meeting were adopted. Regarding the Extraordinary General Meeting, four out of twelve resolutions were adopted.

Bertrand de Castelnaud's cooptation as a Board member was ratified and his mandate was then renewed for a period of three years.

Pierre Morgon, Theradiag's Board of Directors' Chairman, said: *"I would like to sincerely thank all of our shareholders who got involved in this General Meeting - by attending in person or by voting by post or by proxy. The quality of the debate was constructive and allowed us to get a direct feedback on the strategy we committed to implement in the last few months. Regarding our presence in the United States and the recent contract signed, we clarified during this General Meeting that the transfer of our activities to this new partner would be done gradually. This transfer will therefore allow us to build on the foundations we already have on this market."*

"We will continue to capitalize on our full range of biotherapy monitoring tests, accelerate the automation of theranostics and strengthen Theradiag's internationalization, in order to create the conditions for an increased improvement in our profitability. Confidence in our new management team is confirmed, our priorities of development are clear and the first achievements of 2019 are encouraging. Our progress is in line with the plan we have set." added Bertrand de Castelnaud, Theradiag's Chief Executive Officer.

Following this General Meeting, the composition of the Board of Directors is now as follows:

- Pierre Morgon, Chairman of the Board
- Bertrand de Castelnaud, Board member
- Sylvie Bratel, Independent Board member
- Vincent Fert, Board member
- John Li, Board member

The results of the votes of Theradiag's shareholders at this General Meeting were as follows:

	Resolution n°	Resolutions	N° of votes FOR	N° of abstentions	N° of votes AGAINST	Votes	%	Result of the vote
Ordinary General Meeting	1	Approval of financial statements	3,449,827	0	21,000	For Against	99.39% 0.61%	Adopted
	2	Approval of consolidated accounts	3,446,297	0	24,530	For Against	99.29% 0.71%	Adopted
	3	Approval of expenses and liabilities (art. 39 CGI)	3,442,947	0	27,880	For Against	99.20% 0.80%	Adopted
	4	Allocation of 2018 annual income	3,449,827	0	21,000	For Against	99.39% 0.61%	Adopted
	5	Approval of regulated agreements	3,449,827	0	21,000	For Against	99.39% 0.61%	Adopted
	6	Ratification of the cooptation of Mr. Bertrand DE CASTELNAU as a Board member	3,449,827	0	21,000	For Against	99.39% 0.61%	Adopted
	7	Renewal of Mr. Bertrand DE CASTELNAU's mandate as a Board member	3,273,425	0	197,362	For Against	94.31% 5.69%	Adopted
	8	Setting of Board members' attendance fees	2,655,939	1,173	813,715	For Abstention Against	76.52% 0.03% 23.44%	Adopted
	9	Share buyback	3,430,184	713	39,930	For Abstention Against	98.83% 0.02% 1.15%	Adopted
Extraordinary General Meeting	10	Capital increase with pre-emptive subscription rights	3,434,874	713	35,240	For Abstention Against	98.96% 0.02% 1.02%	Adopted
	11	Capital increase without pre-emptive subscription rights via a public offering	1,381,506	0	2,089,321	For Against	39.80% 60.20%	Rejected
	12	Capital increase without pre-emptive subscription rights via a private placement	1,381,506	0	2,089,321	For Against	39.80% 60.20%	Rejected
	13	Capital increase without pre-emptive subscription rights for certain categories of beneficiaries	1,381,950	0	2,088,877	For Against	39.82% 60.18%	Rejected
	14	Increase in the number of shares by virtue of the 4 previous resolutions	1,596,791	32,413	1,841,623	For Abstention Against	46.01% 0.93% 53.06%	Rejected
	15	Common share warrants issue	1,795,309	0	1,675,518	For Against	51.73% 48.27%	Rejected
	16	Free share allotment	1,833,968	0	1,636,859	For Against	52.84% 47.16%	Rejected
	17	Capital increase reserved for employees	405,987	0	3,064,840	For Against	11.70% 88.30%	Rejected
	18	Setting of the global threshold	1,914,012	713	1,556,102	For Abstention Against	55.15% 0.02% 44.83%	Rejected
	19	Reduction of the share capital via the cancellation of shares	3,388,264	0	82,563	For Against	97.62% 2.38%	Adopted
	20	Amendment of the Articles of Association - compliance with legislative and regulatory	3,446,297	0	24,530	For Against	99.29% 0.71%	Adopted
	21	Powers to carry out formalities	3,446,297	0	24,530	For Against	99.29% 0.71%	Adopted



Next financial press release

Half-yearly sales 2019, Thursday 25 July 2019, after market close

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 60 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

ALTER
EURONEXT
GROWTH



Theradiag

Investor Relations

Fabienne François, CFO

Tel.: +33 (0)1 64 62 10 12

contact@theradiag.com

NewCap

Investor Relations

Sandrine Boussard

Tel.: +33 (0)1 44 71 20 40

theradiag@newcap.eu

NewCap

Media Relations

Nicolas Mériageu

Tel.: +33 (0)1 44 71 94 98

nmerigeau@newcap.fr